173 related articles for article (PubMed ID: 9028355)
41. [Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].
Liu F; Jiang B; Gong SJ; Yao BD; Zhang WY; Zhu GS; Zhu ZZ; Gong YF; Wang ML; Hu XH
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):31-4. PubMed ID: 17285540
[TBL] [Abstract][Full Text] [Related]
42. Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
Kashii T; Mizushima Y; Monno S; Nakagawa K; Kobayashi M
J Cancer Res Clin Oncol; 1994; 120(3):143-8. PubMed ID: 8263009
[TBL] [Abstract][Full Text] [Related]
43. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
[TBL] [Abstract][Full Text] [Related]
44. Activation of K-ras in aflatoxin B1-induced lung tumors from AC3F1 (A/J x C3H/HeJ) mice.
Donnelly PJ; Devereux TR; Foley JF; Maronpot RR; Anderson MW; Massey TE
Carcinogenesis; 1996 Aug; 17(8):1735-40. PubMed ID: 8761434
[TBL] [Abstract][Full Text] [Related]
45. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.
Pan ZZ; Wan DS; Chen G; Li LR; Lu ZH; Huang BJ
World J Gastroenterol; 2004 Dec; 10(24):3688-90. PubMed ID: 15534934
[TBL] [Abstract][Full Text] [Related]
46. Incidence of ras oncogene activation in lung carcinomas in Hong Kong.
Lung ML; Wong M; Lam WK; Lau KS; Kwan S; Fu KH; Cheung H; Yew WW
Cancer; 1992 Aug; 70(4):760-3. PubMed ID: 1322782
[TBL] [Abstract][Full Text] [Related]
47. Heterozygous inactivation of TGF-beta1 increases the susceptibility to chemically induced mouse lung tumorigenesis independently of mutational activation of K-ras.
McKenna IM; Ramakrishna G; Diwan BA; Kang Y; Shiao YH; Wakefield LM; Powell DA; Anderson LM; Jakowlew SB
Toxicol Lett; 2001 Sep; 123(2-3):151-8. PubMed ID: 11641043
[TBL] [Abstract][Full Text] [Related]
48. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features.
Hilbe W; Dlaska M; Duba HC; Dirnhofer S; Eisterer W; Oberwasserlechner F; Mildner A; Schmid T; Kühr T; Wöll E
Int J Oncol; 2003 Oct; 23(4):1121-6. PubMed ID: 12963994
[TBL] [Abstract][Full Text] [Related]
49. K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.
Strazisar M; Rott T; Glavac D
Dis Markers; 2008; 25(2):97-106. PubMed ID: 18957720
[TBL] [Abstract][Full Text] [Related]
50. Distribution of p53 and K-ras mutations in human lung cancer tissues.
Gao HG; Chen JK; Stewart J; Song B; Rayappa C; Whong WZ; Ong T
Carcinogenesis; 1997 Mar; 18(3):473-8. PubMed ID: 9067544
[TBL] [Abstract][Full Text] [Related]
51. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
[TBL] [Abstract][Full Text] [Related]
52. Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms.
Couce ME; Bautista D; Costa J; Carter D
Diagn Mol Pathol; 1999 Jun; 8(2):71-9. PubMed ID: 10475381
[TBL] [Abstract][Full Text] [Related]
53. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
Ramirez JL; Sarries C; de Castro PL; Roig B; Queralt C; Escuin D; de Aguirre I; Sanchez JM; Manzano JL; Margelí M; Sanchez JJ; Astudillo J; Taron M; Rosell R
Cancer Lett; 2003 Apr; 193(2):207-16. PubMed ID: 12706879
[TBL] [Abstract][Full Text] [Related]
54. [Detection of K-ras oncogene mutations in human lung cancer by PCR-SSCP-DNA direct sequencing].
Fang Q; Li X; Li J; Liang S
Wei Sheng Yan Jiu; 1998 Jan; 27(1):6-8. PubMed ID: 10682630
[TBL] [Abstract][Full Text] [Related]
55. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction.
Lehman TA; Scott F; Seddon M; Kelly K; Dempsey EC; Wilson VL; Mulshine JL; Modali R
Anal Biochem; 1996 Aug; 239(2):153-9. PubMed ID: 8811898
[TBL] [Abstract][Full Text] [Related]
56. Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases.
Ren YX; Xu GM; Li ZS; Song YG
World J Gastroenterol; 2004 Mar; 10(6):881-4. PubMed ID: 15040037
[TBL] [Abstract][Full Text] [Related]
57. Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer.
Zulhabri O; Rahman J; Ismail S; Isa MR; Wan Zurinah WN
Singapore Med J; 2012 Jan; 53(1):26-31. PubMed ID: 22252179
[TBL] [Abstract][Full Text] [Related]
58. Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing.
Zhang H; Zheng X; Ji T; Fu L; Bai D; Liao Y; Zhang H; Ding Y; Zheng L
Cell Biochem Biophys; 2012 Apr; 62(3):415-20. PubMed ID: 22048888
[TBL] [Abstract][Full Text] [Related]
59. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
60. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy.
Wegman P; Ahlin C; Sorbe B
Int J Gynecol Cancer; 2011 Jan; 21(1):86-91. PubMed ID: 21330833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
